In this Multidisciplinary Roundtable discussion, James Matera, DO, speaks with nephrologist Wayne Kotzker, MD, primary care physician Maria Ciminelli, MD, cardiologist Lance Berger, MD, and nutritionist Jamie Miller, RD, about the role of the multidisciplinary approach in the management of patients with chronic kidney disease (CKD), including referring a patient to a specialist, ensuring risk reduction and slowing the progression of end-stage renal disease, and cardiovascular risk factors in patients with CKD.
In this video, James Matera, DO, speaks with nephrologist Wayne Kotzker, MD, primary care physician, Maria Ciminelli, MD, cardiologist Lance Berger, MD, and nutritionist Jamie Miller, RD, about the role of...
Oxalate nephropathy is a commonly underrecognized cause of chronic kidney disease and end-stage kidney disease with multiple etiologies, including primary hyperoxaluria, enteric hyperoxaluria, or ingestion...
Researchers set out to determine whether renal function could be used as both a predictor of relapse risk for patients with their first onset of aquaporin-4 (AQP4)-immunoglobulin G (IgG)-seropositive...
Utilizing appropriate markers of nutritional status in individuals with chronic kidney disease is essential to providing appropriate care. Do you know which biomarker measurement can be used to predict...
Patients with chronic kidney disease (CKD) are encouraged to maintain a diet that helps manage the disease. Do you know the recommended amount of calcium a person with CKD should ingest every day?
Controversies exist in the management of chronic kidney disease and comorbidities. Do you think the currently available clinical practice guidelines sufficiently address these controversies?
Do you know how long abnormal kidney structure or function should be present before a patient is diagnosed with chronic kidney disease? Test your knowledge with our latest pop quiz!
In this video, James Matera, DO, speaks with nephrologist Wayne Kotzker, MD, primary care physician, Maria Ciminelli, MD, cardiologist Lance Berger, MD, and nutritionist Jamie Miller, RD, about the role of...
In this Q and A, Chief Investigator of the EMPA-KIDNEY trial, William Herrington, MA, MBBS, MD, answers questions about the results of the trial, including the effects of the SGLT2 inhibitor, empagliflozin,...
In this podcast, James Matera, DO, speaks about a patient case presentation of a 41-year-old man with a recurrence of minimal change disease and an incidental finding of papillary renal cell carcinoma on...
In this video, Monica Richey, MSN, ANP-BC/GNP, discusses the clinical challenges and strategies in managing a patient with severe tophaceous gout and stage 3 chronic kidney disease, including urate-lowering...
In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
